Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jakub Żołnierek"'
Autor:
Jakub Żołnierek
Publikováno v:
OncoReview. 11:80-84
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Jakub Żołnierek, Katarzyna Gronostaj, Jakub Kucharz, Anna Czech, Maciej Krzakowski, Piotr J. Wysocki, Krzysztof Małecki, Piotr Chlosta, Paweł Wiechno, Mikolaj Przydacz, Piotr Tomczak, Robert Chrzan, Kamil Konopka
Publikováno v:
Oncology in Clinical Practice. 16:301-330
Autor:
Jakub Żołnierek
Publikováno v:
Oncology in Clinical Practice. 15:303-306
Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important
Autor:
Wojciech Poborski, Piotr J. Wysocki, Jakub Kucharz, Karolina Skalska, Małgorzata Gola, Wojciech Rogowski, Bogumiła Arłukowicz-Czartoryska, Jakub Żołnierek
Publikováno v:
Oncology in Clinical Practice. 15:281-288
Introduction. Cabazitaxel has been approved by the FDA and EMEA for the treatment of metastatic castration- resistant prostate cancer (mCRPC) after failure of docetaxel-based chemotherapy. Between June 2011 and November 2013 cabazitaxel was reimburse
Publikováno v:
Computational Science – ICCS 2022 ISBN: 9783031087561
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::401c5d2e58071739bb464bc58f392b44
https://doi.org/10.1007/978-3-031-08757-8_9
https://doi.org/10.1007/978-3-031-08757-8_9
Autor:
Wojciech Rogowski, Jakub Żołnierek, Aneta Lebiedzińska, Ewa Wachuła, Beata Kos-Kudła, Violeta Sulżyc-Bielicka, Ewa Iżycka-Świeszewska, Anita Gorzelak
Publikováno v:
Endokrynologia Polska. 70:313-317
Introduction: Many retrospective studies have confirmed that capecitabine combined with temozolomide is effective in neuroendocrine neoplasms. Most of the studies focused on grade 1 and grade 2 neuroendocrine tumours, mainly of pancreatic origin. The
Autor:
Magdalena Wieczorek-Rutkowska, Anna Kopczyńska, Lubomir Bodnar, Jakub Żołnierek, Pawel Chrom, Piotr Tomczak
Publikováno v:
Clinical Genitourinary Cancer. 17:e556-e564
Background Cabozantinib is an approved treatment for metastatic renal cell carcinoma (mRCC). This report presents an analysis of the safety profile and efficacy of cabozantinib in an unselected population from Poland. Patients and Methods Patients wi
Autor:
Wojciech Poborski, Piotr Tomczak, Lubomir Bodnar, Jakub Żołnierek, Rafał Stec, Anna M. Czarnecka, Cezary Szczylik, Przemysław Langiewicz
Publikováno v:
Nowotwory. Journal of Oncology. 64:443-453
Autor:
Jakub Żołnierek
Publikováno v:
Współczesna Onkologia. 5:293-304